Morphological and immunohistochemical identification of epithelial-to-mesenchymal transition in clinical prostate cancer

Oncotarget

Volumn 6, Issue 27, 2015, Pages 24488-24498

  Kolijn, Kimberley ^a   Verhoef, Esther I ^a   van Leenders, Geert J L H ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Epithelial to mesenchymal transition; Ill defined; N cadherin; Prostate cancer

Indexed keywords

FIBRONECTIN; NERVE CELL ADHESION MOLECULE; UVOMORULIN; VIMENTIN; CADHERIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER PATIENT; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; GLEASON SCORE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; MALE; PROSTATE CANCER; PROSTATE EPITHELIUM; PROSTATECTOMY; PROTEIN EXPRESSION; TUMOR CELL; BIOSYNTHESIS; GENE EXPRESSION REGULATION; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

AGED; BIOMARKERS, TUMOR; CADHERINS; CELL LINE, TUMOR; EPITHELIAL-MESENCHYMAL TRANSITION; FIBRONECTINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; VIMENTIN;

EID: 84943425036     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4177     Document Type: Article

References (54)

1. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol. 2005;29:1228-1242.
2. Latour M, Amin MB, Billis A, Egevad L, Grignon DJ, Humphrey PA, Reuter VE, Sakr WA, Srigley JR, Wheeler TM, Yang XJ, Epstein JI. Grading of invasive cribriform carcinoma on prostate needle biopsy:an interobserver study among experts in genitourinary pathology. Am J Surg Pathol. 2008;32:1532-1539.
3. Lotan TL, Epstein JI. Gleason grading of prostatic adenocarcinoma with glomeruloid features on needle biopsy. Hum Pathol. 2009;40:471-477.
4. Hay ED. The mesenchymal cell, its role in the embryo, and the remarkable signaling mechanisms that create it. Dev Dyn. 2005;233:706-720.
5. Zhou YC, Liu JY, Li J, Zhang J, Xu YQ, Zhang HW, Qiu LB, Ding GR, Su XM, Mei-Shi;Guo GZ. Ionizing radiation promotes migration and invasion of cancer cells through transforming growth factor-beta-mediated epithelialmesenchymal transition. Int J Radiat Oncol Biol Phys. 2011;81:1530-1537.
6. Sun Y, Wang BE, Leong KG, Yue P, Li L, Jhunjhunwala S, Chen D, Seo K, Modrusan Z, Gao WQ, Settleman J, Johnson L. Androgen deprivation causes epithelialmesenchymal transition in the prostate:implications for androgen-deprivation therapy. Cancer Res. 2012;72:527-536.
7. Perl AK, Wilgenbus P, Dahl U, Semb H, Christofori G. A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature. 1998;392:190-193.
8. Josson S, Sharp S, Sung SY, Johnstone PA, Aneja R, Wang R, Gururajan M, Turner T, Chung LW, Yates C. Tumorstromal interactions influence radiation sensitivity in epithelial-versus mesenchymal-like prostate cancer cells. J Oncol. 2010;doi:10.1155/2010/232831.
9. Birchmeier W, Behrens J. Cadherin expression in carcinomas:role in the formation of cell junctions and the prevention of invasiveness. Biochim Biophys Acta. 1994; 1198:11-26.
10. Jennbacken K, Tesan T, Wang W, Gustavsson H, Damber JE, Welen K. N-cadherin increases after androgen deprivation and is associated with metastasis in prostate cancer. Endocr Relat Cancer. 2010;17:469-479.
11. Marin-Aguilera M, Codony-Servat J, Reig O, Lozano JJ, Fernandez PL, Pereira MV, Jimenez N, Donovan M, Puig P, Mengual L, Bermudo R, Font A, Gallardo E, et al. Epithelial-to-mesenchymal transition mediates docetaxel resistance and high risk of relapse in prostate cancer. Mol Cancer Ther. 2014;13:1270-1284.
12. Gravdal K, Halvorsen OJ, Haukaas SA, Akslen LA. A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer. Clin Cancer Res. 2007;13:7003-7011.
13. Derycke LD, Bracke ME. N-cadherin in the spotlight of cell-cell adhesion, differentiation, embryogenesis, invasion and signalling. Int J Dev Biol. 2004;48:463-476.
14. Tran NL, Nagle RB, Cress AE, Heimark RL. N-Cadherin expression in human prostate carcinoma cell lines. An epithelial-mesenchymal transformation mediating adhesion with stromal cells. Am J Pathol. 1999;155:787-798.
15. Wheelock MJ, Shintani Y, Maeda M, Fukumoto Y, Johnson KR. Cadherin switching. J Cell Sci. 2008;121:727-735.
16. Nieman MT, Prudoff RS, Johnson KR, Wheelock MJ. N-cadherin promotes motility in human breast cancer cells regardless of their E-cadherin expression. J Cell Biol. 1999; 147:631-644.
17. Hazan RB, Phillips GR, Qiao RF, Norton L, Aaronson SA. Exogenous expression of N-cadherin in breast cancer cells induces cell migration, invasion, and metastasis. J Cell Biol. 2000;148:779-790.
18. Brabletz T, Jung A, Reu S, Porzner M, Hlubek F, KunzSchughart LA, Knuechel R, Kirchner T. Variable betacatenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc Natl Acad Sci U S A. 2001;98:10356-10361.
19. Tomita K, van Bokhoven A, van Leenders GJ, Ruijter ET, Jansen CF, Bussemakers MJ, Schalken JA. Cadherin switching in human prostate cancer progression. Cancer Res. 2000;60:3650-3654.
20. Smith A, Teknos TN, Pan Q. Epithelial to mesenchymal transition in head and neck squamous cell carcinoma. Oral Oncol. 2013;49:287-292.
21. Zhu QC, Gao RY, Wu W, Qin HL. Epithelial-mesenchymal transition and its role in the pathogenesis of colorectal cancer. Asian Pac J Cancer Prev. 2013;14:2689-2698.
22. Rees JR, Onwuegbusi BA, Save VE, Alderson D, Fitzgerald RC. In vivo and in vitro evidence for transforming growth factor-beta1-mediated epithelial to mesenchymal transition in esophageal adenocarcinoma. Cancer Res. 2006;66: 9583-9590.
23. Guarino M, Rubino B, Ballabio G. The role of epithelialmesenchymal transition in cancer pathology. Pathology. 2007;39:305-318.
24. Brabletz T, Hlubek F, Spaderna S, Schmalhofer O, Hiendlmeyer E, Jung A, Kirchner T. Invasion and metastasis in colorectal cancer:epithelial-mesenchymal transition, mesenchymal-epithelial transition, stem cells and beta-catenin. Cells Tissues Organs. 2005;179:56-65.
25. Behnsawy HM, Miyake H, Harada K, Fujisawa M. Expression patterns of epithelial-mesenchymal transition markers in localized prostate cancer:significance in clinicopathological outcomes following radical prostatectomy. BJU Int. 2013;111:30-37.
26. Liu GL, Yang HJ, Liu T, Lin YZ. Expression and significance of E-cadherin, N-cadherin, transforming growth factor-beta1 and Twist in prostate cancer. Asian Pac J Trop Med. 2014;7:76-82.
27. Jaggi M, Nazemi T, Abrahams NA, Baker JJ, Galich A, Smith LM, Balaji KC. N-cadherin switching occurs in high Gleason grade prostate cancer. Prostate. 2006;66:193-199.
28. Lang SH, Hyde C, Reid IN, Hitchcock IS, Hart CA, Bryden AA, Villette, JM, Stower MJ, Maitland NJ. Enhanced expression of vimentin in motile prostate cell lines and in poorly differentiated and metastatic prostate carcinoma. Prostate. 2002;52:253-263.
29. Heatley M, Maxwell P, Whiteside C, Toner P. Vimentin and cytokeratin expression in nodular hyperplasia and carcinoma of the prostate. J Clin Pathol. 1995;48:1031-1034.
30. Steinestel K, Eder S, Schrader AJ, Steinestel J. Clinical significance of epithelial-mesenchymal transition. Clin Transl Med. 2014;3:17.
31. Graham TR, Zhau HE, Odero-Marah VA, Osunkoya AO, Kimbro KS, Tighiouart M, Liu T, Simons JW, O'Regan RM. Insulin-like growth factor-I-dependent up-regulation of ZEB1 drives epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Res. 2008;68:2479-2488.
32. Kallakury BV, Sheehan CE, Winn-Deen E, Oliver J, Fisher HA, Kaufman RP Jr, Ross JS. Decreased expression of catenins (alpha and beta), p120 CTN, and E-cadherin cell adhesion proteins and E-cadherin gene promoter methylation in prostatic adenocarcinomas. Cancer. 2001; 92:2786-2795.
33. Chu K, Cheng CJ, Ye X, Lee YC, Zurita AJ, Chen DT, Yu-Lee LY, Zhang S, Yeh ET, Hu MC, Logothetis CJ, Lin SH. Cadherin-11 promotes the metastasis of prostate cancer cells to bone. Mol Cancer Res. 2008;6:1259-1267.
34. Huang CF, Lira C, Chu K, Bilen MA, Lee YC, Ye X, Kim SM, Ortiz A, Wu FL, Logothetis CJ, Yu-Lee LY, Lin SH. Cadherin-11 increases migration and invasion of prostate cancer cells and enhances their interaction with osteoblasts. Cancer Res. 2010;70:4580-4589.
35. Puhr M, Hoefer J, Schäfer G, Erb HH, Oh SJ, Klocker H, Heidegger I, Neuwirt H, Culig Z. Epithelial-tomesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205. Am J Pathol 2012;181:2188-2201.
36. Tanaka H, Kono E, Tran CP, Miyazaki H, Yamashiro J, Shimomura T, Fazli L, Wada R, Huang J, Vessella RL, An J, Horvath S, Gleave M et al. Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance. Nat Med 2010;16: 1414-1420.
37. Wernert N, Seitz G, Achtstatter T. Immunohistochemical investigation of different cytokeratins and vimentin in the prostate from the fetal period up to adulthood and in prostate carcinoma. Pathol Res Pract. 1987;182:617-626.
38. Leong AS, Gilham P, Milios J. Cytokeratin and vimentin intermediate filament proteins in benign and neoplastic prostatic epithelium. Histopathology. 1988;13:435-442.
39. Fraga CH, True LD, Kirk D. Enhanced expression of the mesenchymal marker, vimentin, in hyperplastic versus normal human prostatic epithelium. J Urol. 1998;159:270-274.
40. Li B, Zheng YW, Sano Y, Taniguchi H. Evidence for mesenchymal-epithelial transition associated with mouse hepatic stem cell differentiation. PLoS One. 2011;6: e17092.
41. Kriz W, Kaissling B, Le Hir M. Epithelial-mesenchymal transition (EMT) in kidney fibrosis:fact or fantasy? J Clin Invest. 2011;121:468-474.
42. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J, Weinberg RA. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133:704-715.
43. van der Velden LA, Schaafsma HE, Manni JJ, Link M, Ruiter DJ, Ramaekers FC, Kuijpers W. Cytokeratin and vimentin expression in normal epithelium and benign lesions of the vocal cords. Acta Otolaryngol. 1996;116: 325-331.
44. Park J, Schwarzbauer JE. Mammary epithelial cell interactions with fibronectin stimulate epithelialmesenchymal transition. Oncogene. 2014;33:1649-1657.
45. Albrecht M, Renneberg H, Wennemuth G, Moschler O, Janssen M, Aumuller G, Konrad L. Fibronectin in human prostatic cells in vivo and in vitro:expression, distribution, and pathological significance. Histochem Cell Biol. 1999; 112:51-61.
46. Fernandez-Garcia B, Eiro N, Marin L, GonzalezReyes S, Gonzalez LO, Lamelas ML, Vizoso FJ. Expression and prognostic significance of fibronectin and matrix metalloproteases in breast cancer metastasis. Histopathology. 2014;64:512-522.
47. Han S, Khuri FR, Roman J. Fibronectin stimulates nonsmall cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways. Cancer Res. 2006;66:315-323.
48. Yang Z, Zhang X, Gang H, Li X, Li Z, Wang T, Han J, Luo T, Wen F, Wu X. Up-regulation of gastric cancer cell invasion by Twist is accompanied by N-cadherin and fibronectin expression. Biochem Biophys Res Commun. 2007;358:925-930.
49. Saito N, Nishimura H, Kameoka S. Clinical significance of fibronectin expression in colorectal cancer. Mol Med Rep. 2008;1:77-81.
50. Singh P, Carraher C, Schwarzbauer JE. Assembly of fibronectin extracellular matrix. Annu Rev Cell Dev Biol. 2010;26:397-419.
51. Moroz A, Delella FK, Lacorte LM, Deffune E, Felisbino SL. Fibronectin induces MMP2 expression in human prostate cancer cells. Biochem Biophys Res Commun. 2013;430:1319-1321.
52. Kweldam CF, Wildhagen MF, Steyerberg EW, Bangma CH, van der Kwast TH, van Leenders GJ. Cribriform growth is highly predictive for postoperative metastasis and disease-specific death in Gleason score 7 prostate cancer. Mod Pathol. 2014;28:457-464.
53. Dong F, Yang P, Wang C, Wu S, Xiao Y, McDougal WS, Young RH, Wu CL. Architectural heterogeneity and cribriform pattern predict adverse clinical outcome for Gleason grade 4 prostatic adenocarcinoma. Am J Surg Pathol. 2013;37:1855-1861.
54. Qian J, Jenkins RB, Bostwick DG. Detection of chromosomal anomalies and c-myc gene amplification in the cribriform pattern of prostatic intraepithelial neoplasia and carcinoma by fluorescence in situ hybridization. Mod Pathol. 1997;10:1113-1119.